Recent Updates
Recently added Catalysts

NRX Pharmaceuticals, Inc.

NRXPFDA catalysts, PDUFA dates & pipeline intelligence
$2.55
▼ -0.25 · -8.93%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full NRXP financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.6252W HIGH $5.05
Volume
1.39 M
Value Traded
3.76 M
Short % Float
26.7%
Days to Cover
4.6
+11.84%Week
-2.67%1 Month
-27.35%3 Month
-16.67%6 Month
-98.94%5 Year
-96.65%All Time

Cash Data

Unlock NRXP cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
111.30 M
EPS (TTM)
-0.45
P/E Ratio
-
Ent. Value
91.48 M
Total Shares
43.65 M
Float Shares
39.18 M
Insiders
11.62%
Institutions
32.81%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Approval Decision
NRX-100 (preservative-free ketamine)
depression
Fast Track
NDASmall MoleculesPsychiatry
Unlock every NRXP catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

NRXP Catalyst Timeline

Dated clinical, regulatory and corporate events for NRX Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for NRX Pharmaceuticals, Inc.

663Total events
23Upcoming
185Tier-1 (high impact)
2020 to 2027Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
NRX-100Approved
T2Milestone Payment
Subscribe to view catalyst details
NRX-101Filed

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results and corporate update
●PDUFA DateRegulatory Filing
FDA GDUFA goal date of November 10 for Preservative-Free Ketamine ANDA
▲Product LaunchNRX-100ApprovedPost-Market
NRx commenced selling U.S.-made preservative-free ketamine
▲Product LaunchNRX-100ApprovedPost-Market
NRx began selling preservative-free ketamine with 17-person sales force
◆Timing GuidancePresentation
Conference call scheduled to discuss regulatory milestone for Preservative-Free Ketamine and commercial launch next steps
▲FDA ApprovalFDA Decision
FDA approved ANDA for Preservative-Free Ketamine
▲Manufacturing MilestoneNRX-100ApprovedCMC / Inspection
Two-year room-temperature real-time stability data completed for preservative-free ketamine
▲Manufacturing MilestoneCMC / Inspection
Completion of three commercial Process Validation lots of preservative-free ketamine
●FDA Feedback ReceivedFDA Meeting
FDA Discipline Review Letter requests MINOR label changes for preservative-free ketamine
●Information RequestRegulatory Filing
FDA Discipline Review Letter requests minor label changes for preservative-free ketamine
Unlock the full NRXP catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How NRXP actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-30NRX-100 (preservative-free intravenous ketamine) PDUFA Date ApprovedPDUFA
Unlock 2 more NRXP historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 60%
Micro Cap
(rank 434 of 723)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026)
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
NRX-101 Small MoleculesNCT07227103Treatment Resistant DepressionPhase 2/3 RECRUITING 240Jun 30, 2028
NRX-101 Small MoleculesCompletedNCT02974010Bipolar DepressionPhase 2/3 COMPLETED 104Nov 20, 2019
Unlock the NRXP pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every NRXP program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IV ketamine
Fast Track
treatment resistant depression2026-06-05remission rate iv: 34%; response rate iv: 63%; remission rate nasal esketamine: 26%; response rate nasal esketamine: 58%; odds ratio remission: 1.51; p value remission: <.001; odds ratio response: 1.22; p value response: <.003Read MoreNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.Read More
Scroll for more · summaries link to the source press release
Unlock every NRXP trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock NRXP insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Javitt Jonathan CDirector, Officer (Chairman and Chief Scientist), 10% OwnerBuy 40,000 84,634 held$1.17 12/17/2024
Unlock the full NRXP insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in NRXP for Q3 2026.
Unlock every fund holding NRXP
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in NRXP
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see NRXP ownership
Insider and institutional ownership, quarter by quarter.

NRXP Short Interest

Shares sold short, counted twice a month.

26.7%
Short % of Float
of tradable shares sold short
10.5M
Shares Sold Short
+5.1% vs prior count
4.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.3M
Avg Daily Volume
the average used for days to cover
Unlock NRXP short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock NRXP option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live NRXP option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock NRXP options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How NRXP ranks across every disease it competes in

Competitive Position is a premium feature
See how NRXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

NRXP News

NRXP
Nov 17, 2026
NRXPFDA Updates
▲ +14%on this news· ran to +30% by day 1

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update

NRx Pharmaceuticals reported its third quarter 2026 financial results, highlighting FDA approval of its first drug, preservative-free ketamine. The company has initiated a commercial launch with a 17-person sales team and expects significant market growth. Additionally, NRx announced a collaboration with Yale University to support NRX-100's Accelerated Approval and introduced a new product, NRX-200, for subcutaneous delivery.

Read more →
NRXP
Nov 12, 2026
NRXPConferences/Events

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update

NRx Pharmaceuticals will report its Q3 2026 financial results on November 17, 2026. The company has received significant designations for its drugs, including Fast Track and Breakthrough Therapy for NRX-100 and NRX-101. Additionally, it secured an $11.25 million contract for a phase 3 trial of NRX-101.

Read more →
NRXP
Nov 11, 2026
NRXPGeneral

NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage

NRx Pharmaceuticals has begun selling a new preservative-free ketamine, addressing a shortage that has persisted since 2018. The product is manufactured in the U.S. and utilizes innovative BFS technology, enhancing safety and efficiency. Initial supply agreements are expected by late 2026, with shipments starting in January 2027.

Read more →
NRXP
Oct 30, 2026
NRXPFDA Updates
▼ -14.7%on this news

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

NRx Pharmaceuticals received FDA approval for Preservative-Free Ketamine before the November 10 goal date. This new formulation eliminates the toxic preservative benzethonium chloride, addressing a significant safety concern. The company aims to reshore sterile drug manufacturing in the U.S. to alleviate the current ketamine shortage.

Read more →
NRXP
Oct 29, 2026
NRXPConferences/Events
▼ -14.7%on this newsshared move

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine

NRx Pharmaceuticals will host a conference call on October 30, 2026, to discuss a regulatory milestone for its Preservative-Free Ketamine program. The call will cover next steps for the commercial launch. The company has also received an $11.25 million contract for a phase 3 trial of NRX-101, aimed at treating depression.

Read more →
NRXP
Oct 19, 2026
NRXPFDA Updates

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

NRx Pharmaceuticals has completed the manufacturing process validation for preservative-free Ketamine, ensuring compliance with FDA Good Manufacturing Practices. The company also announced positive two-year stability data, indicating the drug's quality remains intact without toxic preservatives. This positions NRx to supply the product immediately following FDA approval of their ANDA.

Read more →
NRXP
Oct 15, 2026
NRXPFDA Updates

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

NRx Pharmaceuticals has received a Discipline Review Letter from the FDA requesting minor changes to the labeling of its preservative-free ketamine product. The company is required to submit sample labels with the proprietary name under review ahead of the GDUFA goal date of November 10, 2026. NRx is also completing final manufacturing process validation runs for the product launch.

Read more →
NRXP
Sep 30, 2026
NRXPFDA Updates

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

NRx Defense Systems has secured an $11 million DARPA contract to evaluate a novel treatment for resistant depression using robotic TMS and NRX-101. The SPARC-TMS trial aims to validate a one-day treatment protocol that could revolutionize care for military personnel and others suffering from depression. This initiative builds on promising earlier studies showing significant treatment response rates.

Read more →
NRXP
Sep 15, 2026
NRXPFDA Updates

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

NRx Pharmaceuticals has announced that the FDA has reclassified its ANDA amendment for preservative-free ketamine from a Major Amendment to a Minor Amendment. This change has also led to a revision of the GDUFA goal date to November 10, 2026. The company views this as a positive development that may facilitate a quicker approval process for their product.

Read more →
NRXP
Sep 14, 2026
NRXPFDA Updates

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

GeNeuro, Inc. has been awarded a European Patent for GNK-301, a monoclonal antibody aimed at treating Amyotrophic Lateral Sclerosis (ALS). The patent covers the discovery that the HERV K Envelope protein is present in the spinal fluid of many ALS patients and is neurotoxic. The company plans to start Phase I trials in 2027, marking a significant step in ALS treatment development.

Read more →
NRXP
Sep 11, 2026
NRXPFDA Updates

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, is set to deploy the FDA-cleared Zeta TMS Robotic System, enhancing treatment precision for patients with depression. The clinical team is currently training in Boston, and the deployment will support the SPARC-TMS trial of NRX-101. This advancement aims to improve patient outcomes in both military and civilian settings.

Read more →
NRXP
Sep 8, 2026
NRXPConferences/Events

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

NRx Pharmaceuticals will participate in three investor conferences in September 2026, showcasing its clinical-stage developments. CEO Jonathan Javitt will present at the Moody Capital Solutions Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference. The company is focused on developing therapies for central nervous system disorders.

Read more →
NRXP
Aug 17, 2026
NRXPGeneral

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

NRx Pharmaceuticals reported its financial results for Q2 2026, highlighting significant advancements in its drug development programs. The company completed the FDA review for preservative-free ketamine and initiated commercial manufacturing. Additionally, NRx was selected by DARPA for a Phase 2/3 trial of NRX-101, aiming for broader treatment applications. Financially, the company reported a net loss but secured substantial funding to support operations.

Read more →
NRXP
Aug 7, 2026
NRXPConferences/Events
▼ -6.4%on this news

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

NRx Pharmaceuticals announced a conference call on August 10, 2026, to discuss the FDA's completion of the first-cycle review of its ANDA for preservative-free ketamine. Key executives will participate, addressing regulatory pathways and commercial plans. The call will be accessible via webcast and telephone, with a replay available afterward.

Read more →
NRXP
Aug 7, 2026
NRXPFDA Updates
▲ +15.9%on this newsshared move

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

NRx Pharmaceuticals announced that the FDA has completed the first-cycle review of its preservative-free ketamine ANDA, identifying no major deficiencies. The only remaining requirement is a certification related to the medication vial's luer lock tip. NRx views this outcome as a significant regulatory milestone that reduces risks for commercialization. A conference call is scheduled for August 10, 2026, to discuss further developments.

Read more →
NRXP
Jun 25, 2026
NRXPGeneral

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

NRx Pharmaceuticals has responded to Kadima Neuropsychiatry Institute's recent allegations regarding a failed acquisition by HOPE Therapeutics. NRx has initiated arbitration due to Kadima's failure to meet key conditions. The company emphasizes its focus on drug development and innovative treatments, particularly in personalized medicine and TMS technology, despite the ongoing dispute.

Read more →
NRXP
Jun 25, 2026
NRXPGeneral

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has initiated treatments using the FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This marks a significant transition to active patient care, utilizing AI for precise targeting in TMS therapies for Major Depressive Disorder and other CNS conditions. The deployment supports HOPE's interventional psychiatry platform and aligns with planned clinical trials for NRX-101.

Read more →
NRXP
Jun 23, 2026
NRXPGeneral

ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

ZETA SURGICAL and HOPE Therapeutics announced the successful treatment of the first patient using the Zeta TMS Navigation System, which is FDA-cleared. This system utilizes advanced AI and computer vision for precise targeting in TMS therapy, primarily for treatment-resistant depression. The technology aims to enhance patient outcomes and expand access to personalized care.

Read more →
NRXP
Jun 22, 2026
NRXPFDA Updates

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals has received FDA approval for an Expanded Access Protocol for NRX-101, a combination of D-cycloserine and lurasidone, aimed at augmenting Transcranial Magnetic Stimulation (TMS) for patients with Treatment-Resistant Depression. This protocol allows patients who cannot participate in clinical trials to access the treatment. The company is also conducting a pivotal trial to assess the efficacy of NRX-101 in achieving remission from depression and suicidality.

Read more →
NRXP
Jun 5, 2026
NRXPConferences/Events

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

NRx Pharmaceuticals announced a presentation at the American Society of Clinical Psychopharmacology, highlighting a study comparing IV ketamine and nasal esketamine for treating depression. The study found that IV ketamine resulted in higher remission and response rates among patients. However, it noted limitations due to non-randomized treatment assignments and potential confounding variables.

Read more →

About NRX Pharmaceuticals, Inc.

Wilmington, DE 29 employees nrxpharma.com
Headquarters1201 ORANGE STREET, WILMINGTON, DE, 19801
BIOPHARMAWATCH ELITE
Trade the next NRXP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime